Investor Relations

Announcements and Others

Date Year  
2017.12.11 Announcements and Notices - Framework Agreement
2017.12.08 Announcements and Notices - Interim Results for the Six Months Ended 31 October 2017
2017.12.04 Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2017
2017.12.04 Company Information Sheet
2017.11.30 Announcements and Notices - List of Directors and Their Role and Function
2017.11.30 Announcements and Notices - (1) Resignation of Executive Director and Vice-chairman (2) Change of Authorised Representative (3) Change of Compliance Officer (4) Change of Process Agent
2017.11.28 Announcements and Notices - Notice of Board Meeting
2017.11.07 Announcements and Notices - Update Announcement on Investment in A Fund
2017.11.03 Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2017
2017.10.18 Announcement in Relation to Expected Gain on Disposal of A Subsidiary
2017.10.17 (1) Clarification; and (2) Business Update
2017.10.06 Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2017
2017.09.28 Change of Financial Year End Date
2017.09.21 Voluntary Announcement Mr. Dai Yumin Acquired 40% All Favour and Became the Sole Beneficial Owner of All Favour
2017.09.19 Voluntary Announcement Letter of Intent
2017.09.19 Voluntary Announcement Increase in Shareholding by Substantial Shareholder
2017.09.15 Company Information Sheet
2017.09.15 List of Directors and Their Role and Function
2017.09.15 Resignation of Independent Non-executive Director and Change of Composition of Board Committees
2017.09.08 First Quarterly Results for the Three Months Ended 31 July 2017
2017.09.08 Company Information Sheet
2017.09.08 List of Directors and Their Role and Function
2017.09.08 (1) Poll Results of the Annual General Meeting Held on 8 September 2017; (2) Resignation of Executive Director and Non-executive Director; (3) Re-designation of Director; (4) Change of Authorised Representative; and (5) Change of Composition of Board Committees
2017.09.05 "Acornea" Expands Clinical Applications Completed FDA Registration
2017.09.05 Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 August 2017
2017.08.29 Mrs. Carrie Lam Cheng Yuet-ngor, the Chief Executive of Hong Kong Sar, Visited Binhai New District, Tianjin and Received the Management of Tianjin Weikai Bioeng, A Subsidiary of China Regenerative Medicine
2017.08.29 Voluntary Announcement Increase in Shareholding by Substantial Shareholder
2017.08.29 Notice of Board Meeting
2017.08.02 Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 July 2017
2017.07.28 China Regenerative Medicine Establishing A Joint Laboratory on Regenerative Medicine Technology under the National Engineering Research Center for Ophthalmology Improving Product Technologies of the Company and Facilitating the Development of Ophthalmic Technology
2017.07.27 Proxy Form for the Annual General Meeting
2017.07.27 Notice of Annual General Meeting
2017.07.18 Clarification Announcement
2017.07.18 Investment in A Fund
2017.07.17 Annual Results Announcement for the Year Ended 30 April 2017
2017.07.17 Poll Results of Extraordinary General Meeting Held on 17 July 2017
2017.07.17 Investment in A Fund
2017.07.05 Notice of Board Meeting
2017.07.05 Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 30 June 2017
2017.07.05 Bio-engineered Cornea "acornea" Listed As A Multicenter Research Subject for Clinical Applications of Scientific Research Plan of Blindness Prevention of National Health and Family Planning Commission of China
2017.06.26 Proxy Form for the Extraordinary General Meeting
2017.06.26 Notice of Extraordinary General Meeting
2017.06.26 Business Updates Financial Performance Targets
2017.06.23 Products Return
2017.06.16 Business Update Inauguration of HK International Regenerative Centre and China Stem Cell Clinical Applications Centre
2017.06.01 Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 May 2017
2017.06.01 Company Information Sheet
2017.06.01 List of Directors and their Role and Function
2017.05.31 (1) Re-designation of Director and Appointment of Chief Overseas Mergers and Acquisitions Officer and (2) Change of Principal Place of Business in Hong Kong
2017.05.04 Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 30 April 2017
2017.04.05 Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 March 2017
2017.03.31 Proposed Subscription for Interest in A Fund
2017.03.20 Proposed Grant of Share Options to Executive Director
2017.03.20 List of Directors and their Role and Function
2017.03.20 Company Information Sheet
2017.03.20 Appointment of Non-executive Director
2017.03.16 Third Quarterly Results for the Nine Months Ended 31 January 2017
2017.03.14 Voluntary Announcement Increase in Shareholding by Substantial Shareholder
2017.03.14 Update on the Accounting Treatment of the Lease Agreements
2017.03.13 Voluntary Announcement Increase in Shareholding by Substantial Shareholder
2017.03.10 Voluntary Announcement Increase in Shareholding by Substantial Shareholder
2017.03.09 Voluntary Announcement Increase in Shareholding by Substantial Shareholder
2017.03.08 Voluntary Announcement Increase in Shareholding by Substantial Shareholder
2017.03.03 Notice of Board Meeting
2017.03.03 Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 28 February 2017
2017.02.23 Company Information Sheet
2017.02.23 List of Directors and their Role and Function
2017.02.23 (1) Appointment of Independent Non-executive Director; (2) Appointment of Non-executive Director and Global Chief Strategy Officer; (3) Change in Executive Functions; (4) Change of Chief Executive Officer; and (5) Changes in Committees Composition
2017.02.03 Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 January 2017
2017.01.25 Company Information Sheet (GEM )
2017.01.25 List of Directors and their Role and Function
2017.01.25 (1) Appointment of an Executive Director and (2) Proposed Grant of Share Options
2017.01.12 (1) Completion of the Disposal of Debt Receivables and Associated Security Package; and (2) Discloseable Transaction - Lease Agreements
2017.01.05 Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 December 2016

IR Contact

China Regenerative Medicine International Limited

A:

10/F, Dah Sing Financial Center, 108 Gloucester Road, Wan chai, Hong Kong

E: info@crmi.hk|

T: +852 3966 8388 |

F: +852 2802 0026